Treatment with checkpoint inhibitors for unresectable non-metastatic mismatch repair deficient intestinal cancer; a case series
A selection of patients included in this study were part of the ATAPEMBRO study, a single-centre, open label, phase 1-2 study (NCT04014530).
Authors
- Adriaan D. Bins
- Frank J. Jeurissen (ORCID: https://orcid.org/0009-0005-3881-1065)
- Tineke E. Buffart (ORCID: https://orcid.org/0000-0003-2464-7741)
- Jurriaan B. Tuynman (ORCID: https://orcid.org/0000-0001-5952-8000)
- Orlane Figaroa (ORCID: https://orcid.org/0000-0002-5284-3515)
- Geert A. Cirkel (ORCID: https://orcid.org/0009-0007-8712-9825)
- Ruben S. A. Goedegebuure
- Ide Spaanderman (ORCID: https://orcid.org/0000-0002-5560-4739)
- G.J. Creemers
Institutions
- Radboud University Nijmegen (NL)
- Dutch Cancer Society (NL)
- Catharina Ziekenhuis (NL)
- Medisch Centrum Haaglanden (NL)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- Meander Medisch Centrum (NL)
- Cancer Center Amsterdam (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- BJC Reports
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1038/s44276-025-00171-0
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09